Anti-HBV surface antigen (Libivirumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-HBV surface antigen (Libivirumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (ADC-W-1975)
This ADC product is comprised of an anti-HBV surface antigen monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
ADC Target
Name
HBV surface antigen
Alternative Names
HBV surface antigen
Overview
Hepatitis B surface antigen (HBsAg) has been the principal target for laboratory testing to identify active infection by HBV.
ADC Antibody
Overview
Human Anti-HBV surface antigen IgG1-kappa antibody, Libivirumab
Generic name
Libivirumab
Host animal
Human
ADC Linker
Name
MC-Vc-PAB-DMEA-(PEG2)
Description
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
Name
duocarmycin SA
Description
Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.